Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julia-Annabell Georgi

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Frontiers in Oncology|March 7, 2022
Analysis of Subset Chimerism for MRD-Detection and Pre-Emptive Treatment in AMLJulia-Annabell Georgi, Sebastian Stasik, Martin Bornhäuser, et al.
Blood Advances|April 12, 2023
Deciphering the genetic basis of immune thrombocytopenia: current evidence for genetic predisposition in adult ITPJulia-Annabell Georgi, Jan Moritz Middeke, Martin Bornhäuser, et al.
Annals of Hematology|February 4, 2026
Relapse following FLT3 inhibitor cessation in FLT3-ITD-positive AML: lessons from two clinical casesJulia-Annabell Georgi, Christoph Röllig, Johannes Schetelig, et al.
British Journal of Haematology|February 25, 2026
Fostamatinib treatment for patients with antiphospholipid syndrome and low platelet count: A case seriesEkaterina Balaian, Rosa Sonja Alesci, Sandra Marten, et al.
Annals of Hematology|January 12, 2024
VEXAS syndrome: complete molecular remission after hypomethylating therapyKatja Sockel, Katharina Götze, Christina Ganster, et al.
Journal of Thrombosis and Haemostasis : JTH|July 4, 2026
RNA Sequencing Indicates Distinct Platelet Transcriptomic Changes in Immune ThrombocytopeniaJulia-Annabell Georgi, Marita Hartwig, Ulrike Anne Friedrich, et al.
Communications Medicine|May 17, 2023
Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profilesJan-Niklas Eckardt, Christoph Röllig, Klaus Metzeler, et al.
Haematologica|June 16, 2022
Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learningJan-Niklas Eckardt, Christoph Röllig, Klaus Metzeler, et al.
Blood|December 8, 2025
Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trialAnne Sophie Platzbecker, Julia Annabell Georgi, Jan Moritz Middeke, et al.
Blood Cancer Journal|May 26, 2023
UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcomeJulia-Annabell Georgi, Sebastian Stasik, Jan-Niklas Eckardt, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Frontiers in Oncology|March 7, 2022
Analysis of Subset Chimerism for MRD-Detection and Pre-Emptive Treatment in AMLJulia-Annabell Georgi, Sebastian Stasik, Martin Bornhäuser, et al.
Blood Advances|April 12, 2023
Deciphering the genetic basis of immune thrombocytopenia: current evidence for genetic predisposition in adult ITPJulia-Annabell Georgi, Jan Moritz Middeke, Martin Bornhäuser, et al.
Annals of Hematology|February 4, 2026
Relapse following FLT3 inhibitor cessation in FLT3-ITD-positive AML: lessons from two clinical casesJulia-Annabell Georgi, Christoph Röllig, Johannes Schetelig, et al.
British Journal of Haematology|February 25, 2026
Fostamatinib treatment for patients with antiphospholipid syndrome and low platelet count: A case seriesEkaterina Balaian, Rosa Sonja Alesci, Sandra Marten, et al.
Annals of Hematology|January 12, 2024
VEXAS syndrome: complete molecular remission after hypomethylating therapyKatja Sockel, Katharina Götze, Christina Ganster, et al.
Journal of Thrombosis and Haemostasis : JTH|July 4, 2026
RNA Sequencing Indicates Distinct Platelet Transcriptomic Changes in Immune ThrombocytopeniaJulia-Annabell Georgi, Marita Hartwig, Ulrike Anne Friedrich, et al.
Communications Medicine|May 17, 2023
Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profilesJan-Niklas Eckardt, Christoph Röllig, Klaus Metzeler, et al.
Haematologica|June 16, 2022
Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learningJan-Niklas Eckardt, Christoph Röllig, Klaus Metzeler, et al.
Blood|December 8, 2025
Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trialAnne Sophie Platzbecker, Julia Annabell Georgi, Jan Moritz Middeke, et al.
Blood Cancer Journal|May 26, 2023
UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcomeJulia-Annabell Georgi, Sebastian Stasik, Jan-Niklas Eckardt, et al.
Pageof 2